Shanghai Pharmaceuticals Holding Co., Ltd

SEHK:2607 Stock Report

Market Cap: HK$71.8b

Shanghai Pharmaceuticals Holding Valuation

Is 2607 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2607 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
HK$9.77
Fair Value
26.6% overvalued intrinsic discount
7
Number of Analysts

Below Fair Value: 2607 (HK$12.36) is trading above our estimate of fair value (HK$9.77)

Significantly Below Fair Value: 2607 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2607?

Key metric: As 2607 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 2607. This is calculated by dividing 2607's market cap by their current earnings.
What is 2607's PE Ratio?
PE Ratio18.6x
EarningsCN¥4.03b
Market CapCN¥66.77b

Price to Earnings Ratio vs Peers

How does 2607's PE Ratio compare to its peers?

The above table shows the PE ratio for 2607 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average9.3x
1099 Sinopharm Group
6.9x4.4%HK$64.1b
874 Guangzhou Baiyunshan Pharmaceutical Holdings
7.7x2.5%HK$44.5b
1931 IVD Medical Holding
10.6xn/aHK$3.0b
3390 Tycoon Group Holdings
11.9xn/aHK$2.7b
2607 Shanghai Pharmaceuticals Holding
18.6x17.3%HK$66.8b

Price-To-Earnings vs Peers: 2607 is expensive based on its Price-To-Earnings Ratio (18.6x) compared to the peer average (9.3x).

Price to Earnings Ratio vs Industry

How does 2607's PE Ratio compare vs other companies in the HK Healthcare Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
574 Pa Shun International Holdings
2.1xn/aUS$9.66m
No more companies available in this PE range
No. of Companies8PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 2607 is expensive based on its Price-To-Earnings Ratio (18.6x) compared to the Hong Kong Healthcare industry average (12.6x).

Price to Earnings Ratio vs Fair Ratio

What is 2607's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2607 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.6x
Fair PE Ratio19x

Price-To-Earnings vs Fair Ratio: 2607 is good value based on its Price-To-Earnings Ratio (18.6x) compared to the estimated Fair Price-To-Earnings Ratio (19x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target
Consensus Narrative from 7 Analysts
HK$13.05
Fair Value
5.3% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 04:25
End of Day Share Price 2025/01/28 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Pharmaceuticals Holding Co., Ltd is covered by 49 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xing Qiu LinAJ Securities Co., Ltd
Zhi Xue DiaoAvic Securities Co., Ltd
Derrick SunBNP Paribas Securities (Asia)